Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
4DMedical Ltd ( (AU:4DX) ) has issued an announcement.
4DMedical has secured CE Mark certification for its CT:VQ™ ventilation-perfusion imaging technology, clearing the way for commercial deployment across the European Union, one of the world’s largest markets for cardiothoracic imaging. The non-contrast, CT-based solution aims to address constraints in traditional nuclear VQ imaging by leveraging existing CT infrastructure and is expected to strengthen the company’s clinical and research collaborations with leading European respiratory centres.
In tandem with the regulatory win, the company has raised $83 million via a private placement priced at $5.90 per share, a modest discount to the last close but at a premium to the recent VWAP, resulting in a 2.45% increase in shares on issue. The funds will support CT:VQ™’s European and broader international rollout, integration with new customers, and potential strategic growth initiatives, reinforcing 4DMedical’s cash position and its bid to replicate its early U.S. adoption success in the EU.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$6.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is an Australian-listed medical technology company specialising in advanced respiratory imaging solutions. Its flagship product, CT:VQ™, provides non-contrast, CT-based ventilation-perfusion imaging to support diagnosis and management of cardiopulmonary conditions, with a growing focus on major hospital networks in the U.S. and Europe.
Average Trading Volume: 7,573,431
Technical Sentiment Signal: Buy
Current Market Cap: A$3.58B
Find detailed analytics on 4DX stock on TipRanks’ Stock Analysis page.